Evidence map›Paper›PMID 39320608›Full record

ReviewMedical oncology (Northwood, London, England)2024

Personalized treatment approach for HER2-positive metastatic breast cancer.

Prashant Pandey, Rishabh Chaudhary, Devika Tripathi, Kousalya Lavudi, Kamal Dua, Michael Weinfeld, Afsaneh Lavasanifar, P S Rajinikanth

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Prashant PandeyFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
Rishabh ChaudharyDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India.
Devika TripathiPSIT-Pranveer Singh Institute of Technology (Pharmacy), Kanpur, India.
Kousalya LavudiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Michael WeinfeldCross Cancer Institute and Department of Oncology, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
Afsaneh LavasanifarFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
P S RajinikanthDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India. psrajinikanth222@gmail.com.

Funding

Science and Engineering Research Board SB/S9/Z-16/2016-IV (2022)
6 · The paper itself

Abstract

Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPrecision MedicineAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleHumansImmunotherapyMolecular Targeted TherapyNeoplasm MetastasisAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAnti-HER2Breast cancerHER2ImmunotherapyLiquid biopsyLocoregional

Identifiers

PMID39320608

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.